Possible mechanisms for N-acetyl cysteine and taurine in ameliorating acute renal failure induced by cisplatin in rats

Toxicology Mechanisms and Methods

Volumn 21, Issue 7, 2011, Pages 538-546

  Shalby, Aziza B ^a   Assaf, Naglaa ^b   Ahmed, Hanaa H ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Misr University for Science and Technology   (Egypt)

Author keywords

Inflammation; NAC; Nephrotoxicity; Oxidative stress; TAU

Indexed keywords

ACETYLCYSTEINE; BETA 2 MICROGLOBULIN; CISPLATIN; CREATININE; N ACETYL BETA GLUCOSAMINIDASE; TAURINE; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; UREA BLOOD LEVEL;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; KIDNEY; KIDNEY FUNCTION TESTS; LIPID PEROXIDATION; RATS; RATS, SPRAGUE-DAWLEY; TAURINE;

RATTUS;

EID: 80051723848     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2011.568985     Document Type: Article

References (71)

1. Alencar JL, Lobysheva I, Geffard M, Sarr M, Schott C, Schini-Kerth VB, Nepveu F, Stoclet JC, Muller B. 2003. Role of S-nitrosation of cysteine residues in long-lasting inhibitory effect of nitric oxide on arterial tone. Mol Pharmacol 63:1148-1158. (Pubitemid 36529933)
2. Aruoma OI, Halliwell B, Hoey BM, Butler J. 1989. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6:593-597. (Pubitemid 19147809)
3. Banday AA, Farooq N, Priyamvada S, Yusufi AN, Khan F. 2008. Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. Life Sci 82:450-459.
4. Barua M, Liu Y, Quinn MR. 2001. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-α gene expression in activated alveolar macrophages: Decreased NF-κβ activation and Iκβ Kinase activity. J Immunol 167:2275-2281. (Pubitemid 32747540)
5. Berkels R, Purol-Schnabel S, Roesen R. 2004. Measurement of nitric oxide by reconversion of nitrate/nitrite to N. J Human Press 279:1-8.
6. Border WA, Noble NA. 1997. TGF-beta in kidney fibrosis: A target for gene therapy. Kidney Int 51:1388-1396. (Pubitemid 27239888)
7. Bonegio R, Lieberthal W. 2005. Cisplatin-induced nephrotoxicity. Toxicology of the kidney. 3rd edn. Boca Raton; pp 779-815.
8. Boulikas T, Vougiouka M. 2004. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (Review). Oncol Rep 11:559-595.
9. Bradford RW, Allen HW. 1996. Taurine in health and disease. J Adv Med 9:179-199.
10. Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G, Gullans SR. 1990. Mitochondrial injury: An early event in cisplatin toxicity to renal proximal tubules. Am J Physiol 258:F1181-F1187. (Pubitemid 20185251)
11. Brady HR, Zeidel ML, Kone BC, Giebisch G, Gullans SR. 1993. Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells. J Pharmacol Exp Ther 265:1421-1428. (Pubitemid 23321051)
12. Chirino YI, Pedraza-Chaverri J. 2009. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61:223-242.
13. Corti A, Fassino J, Marcucci F, Barbenti E, Cassani G. 1992. Oligometric tumor necrosis factor-β slowly converts into the reactive forms at bioactive levels. Biochem J 284:905-910.
14. Crisp AJ, Coughlan RJ, Mackintosh D, Clark B, Panayi GS. 1983. β2-microglobulin plasma level reflects disease activity in rheumatoid arthritis. J Rheumatoid 10:954-956. (Pubitemid 14156289)
15. Cruz CI, Ruiz-Torres P, del Moral RG, Rodríuez-Puyol M, Rodríuez-Puyol D. 2000. Age-related progressive renal fibrosis in rats and its prevention with ACE inhibitors and taurine. Am J Physiol Renal Physiol 278:F122-F129. (Pubitemid 30106133)
16. Dajak M, Ignjatovic S, Stojimirovic B, Gajic S, Majkic-Singh N. 2010. Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease. Clin Chim Acta 411:1154-1155.
17. Della Corte L, Crichton RR, Duburs G, Nolan K, Tipton KF, Tirzitis G, Ward RJ. 2002. The use of taurine analogues to investigate taurine functions and their potential therapeutic applications. Amino Acids 23:367-379. (Pubitemid 35435595)
18. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC. 1994. Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 266:F926-F933.
19. Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Kraemer DF, Neuwelt EA. 2008. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother Pharmacol 62:235-241. (Pubitemid 351692079)
20. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. 2005. Protection against cisplatin-induced toxicities by N-acetyl cysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314:1052-1058. (Pubitemid 41205968)
21. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Ćar LA, Seguro AC. 2004. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: Decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19:1803-1807. (Pubitemid 38961391)
22. El-Hamamsy I, Stevens LM, Carrier M, Pellerin M, Bouchard D, Demers P, Cartier R, Page P, Perrault LP. 2007. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 133:7-12. (Pubitemid 46014198)
23. Ekor M, Emerole GO, Farombi EO. 2010. Phenolic extract of soybean (Glycine max) attenuates cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 48:1005-1012.
24. Eppler B, Dawson R Jr. 2002. Cytoprotective role of taurine in a renal epithelial cell culture model. Biochem Pharmacol 63:1051-1060. (Pubitemid 34267020)
25. Esterbauer H, Schaure RJ, Zollner H. 1991. Chemistry and biochemistry of 4- hydroxynonenal. Malonaldehyde and related aldehydes. Free Rad Biol Med 11:81-128. (Pubitemid 121003917)
26. Evans P, Halliwell B. 1999. Free radicals and hearing. Cause, consequence, and criteria. Ann N Y Acad Sci 884:19-40.
27. Fawcett JK, Scott JEC. 1960. A rapid and precise method for determination of urea. J Clin Pathol 13:156-159.
28. Gaull GE. 1989. Taurine in pediatric nutrition: Review and update. Pediatrics 83:433-442. (Pubitemid 19071768)
29. Grande J, Melder D, Zinsmeister A, Killen P. 1993. Transforming growth factor-beta 1 induces collagen IV gene expression in NIH- 3T3 cells. Lab Invest 69:387-395.
30. Gressner AM, Roebruk P. 1982. Predictive values of serum N-acetylbeta- D glucosaminidase for fibroid liver disorders, correlation with monoamine oxidase activity. Clin Chim Acta 124:315-326. (Pubitemid 12030882)
31. Guan X, Dei-Anane G, Liang R, Gross ML, Nickkholgh A, Kern M, Ludwig J, Zeier M, Bühler MW, Schmidt J, Schemmer P. 2008. Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. J Surg Res 146:127-134. (Pubitemid 351442941)
32. Han X, Chesney RW. 2009. Mechanism of TauT in protecting against cisplatin-induced kidney injury (AKI). Adv Exp Med Biol 643:105-112.
33. Hannemann J, Baumann K. 1988. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: Different effects of antioxidants and radical scavengers. Toxicology 51:119-132.
34. Hassan MI, Ahmed MI, Kassim SK, Rashad A, Khalifa A. 1999. Cis-platinum-induced immunosuppression: Relationship to melatonin in human peripheral blood mononuclear cells. Clin Biochem 32:621-626. (Pubitemid 30039090)
35. Heller-Stilb B, van Roeyen C, Rascher K, Hartwig HG, Huth A, Seeliger MW, Warskulat U, H́ssinger D. 2002. Disruption of the taurine transporter gene (TauT) leads to retinal degeneration in mice. FASEB J 16:231-233.
36. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. 1995. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270:1842-1845. (Pubitemid 26007235)
37. Ikawa T, Ikeda M, Yamaguchi A, Tsai WC, Tamura N, Seta N, Trucksess M, Raybourne RB, Yu DT. 1998. Expression of arthritis-causing HLA-B27 on HeLa cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. J Clin Invest 101:263-272. (Pubitemid 28058926)
38. Khan MR, Siddiqui S, Parveen K, Javed S, Diwakar S, Siddiqui WA. 2010. Nephroprotective action of tocotrienol-rich fraction (TRF) from palm oil against potassium dichromate (K 2 Cr 2 O 7)-induced acute renal injury in rats. Chem Biol Interact 186:228-238.
39. Kim SJ, Romeo D, Yoo YD, Park K. 1994. Transforming growth factorbeta: Expression in normal and pathological conditions. Horm Res 42:5-8. (Pubitemid 24235632)
40. Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. 2001. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 54:356-361. (Pubitemid 32458132)
41. Larsen, K. 1972. Creatinine assay by a reaction kinetic principle. Clin Chem Acta 41:209-217.
42. Luo J, Tsuji T, Yasuda H, Sun Y, Fujigaki Y, Hishida A. 2008. The molecular mechanisms of the attenuation of cisplatin- induced acute renal failure by N-acetylcysteine in rats. Nephrol Dial Transplant 23:2198-2205. (Pubitemid 351957613)
43. Maldonado V, Meĺdez-Zajgla J, Ortega A. 1997. Modulation of NF-kappa B, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Mutat Res 381:67-75. (Pubitemid 27504568)
44. Mãsuda H, Tanaka T, Takahama U. 1994. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 203:1175-1180. (Pubitemid 24304953)
45. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. 2009. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm 71:190-195.
46. Mishima K, Baba A, Matsuo M, Itoh Y, Oishi R. 2006. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med 40:1564-1577.
47. Nisar S, Feinfeld DA. 2002. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Ren Fail 24:529-533. (Pubitemid 34913063)
48. Okuda M, Mãsaki K, Fukatsu S, Hashimoto Y, Inui K. 2000. Role of apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. Implication of the functions of apical membranes. Biochem Pharmacol 59:195-201.
49. Ramesh G, Reeves WB. 2003. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610-F618. (Pubitemid 37140245)
50. Ramesh G, Reeves WB. 2005. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166-F174. (Pubitemid 40863584)
51. Ramesh G, Reeves WB. 2002. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842.
52. Ramesh G, Reeves WB. 2004. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 65:490-499.
53. Saad SY, Al-Rikabi AC. 2002. Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 48:42-48. (Pubitemid 34233885)
54. Salahudeen A, Poovala V, Parry W, Pande R, Kanji V, Ansari N, Morrow J, Roberts J 2nd. 1998. Cisplatin induces N-acetyl cysteine suppressible F2-isoprostane production and injury in renal tubular epithelial cells. J Am Soc Nephrol 9:1448-1455. (Pubitemid 28354555)
55. Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M. 2002. Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 365:277-283. (Pubitemid 34280366)
56. Schafer FQ, Buettner GR. 2001. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/ glutathione couple. Free Radic Biol Med 30:1191-1212. (Pubitemid 32463931)
57. Schafer S, Azuma J, Takahashi K. 2003. Why is taurine cytoprotective? New York: Kluwer Academic/Plenum Publishers, 307.
58. Schuller-Levis GB, Park E. 2003. Taurine: New implications for an old amino acid. FEMS Microbiol Lett 226:195-202. (Pubitemid 38444940)
59. Sener G, Sehirli O, Iṕ Y, Cetinel S, Cikler E, Gedik N, Alican I. 2005. Protective effects of taurine against nicotine-induced oxidative damage of rat urinary bladder and kidney. Pharmacology 74:37-44. (Pubitemid 40591462)
60. Shin HK, Linkswiler HM. 1974. Tryptophan and methionine metabolism of adult females as affected by vitamin B-6 deficiency. J Nutr 104:1348-1355.
61. Sorbello M, Morello G, Parrinello L, Molino C, Rinzivillo D, Pappalardo R, Cutuli M, Corona D, Veroux P, Veroux M. 2010. Effect of N-acetylcysteine (NAC) added to fenoldopam or dopamine on end-tidal carbon dioxide and mean arterial pressure at time of renal artery declamping during cadaveric kidney transplantation. Transplant Proc 42:1056-1060.
62. Sugihara K, Nakano S, Koda M, Tanaka K, Fukuishi N, Gemba M. 1987. Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Jpn J Pharmacol 43:247-252. (Pubitemid 17034954)
63. Townsend DM, Hanigan MH. 2002. Inhibition of γ- glutamyl transpeptidase or cysteine S-conjugate β-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exptl Ther 300:142-148. (Pubitemid 34028520)
64. Videhult P, Laurell G, Wallin I, Ehrsson H. 2006. Kinetics of cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. Exp Biol Med (Maywood) 231:1638-1645. (Pubitemid 44808368)
65. Winterbourn CC, Metodiewa D. 1995. Reaction of superoxide with glutathione and other thiols. Meth Enzymol 251:81-86.
66. Yamate J, Machida Y, Ide M, Kuwamura M, Sawamoto O, Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol O. 2003. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacological Research 47: 149-156. (Pubitemid 36263450)
67. Yoshida M, Fukuda A, Hara M, Terada A, Kitanaka Y, Owada S. 2003. Melatonin prevents the increase in hydroxyl radical-spin trap adduct formation caused by the addition of cisplatin in vitro. Life Sci 72:1773-1780. (Pubitemid 36136080)
68. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol O. 2003. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 47:149-156. (Pubitemid 36263450)
69. Zhang JG, Lindup WE. 1996. Differential effects of cisplatin on the production of NADH-dependent superoxide and the activity of antioxidant enzymes in rat renal cortical slices in vitro. Pharmacol Toxicol 79:191-198. (Pubitemid 26338724)
70. Zhang RK. 1995. Organic Anion Transport and Action of Glutamyl- Transpeptidase in Kidney Linked Mechanistically to Renal Tubule Uptake of Inorganic Mercury. Toxicol Appl Pharmacol 132:289-289.
71. Zhou H, Kato A, Miyaji T, Yasuda H, Fujigaki Y, Yamamoto T, Yonemura K, Takebayashi S, Mineta H, Hishida A. 2006. Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. Nephrol Dial Transplant 21:616-623. (Pubitemid 43372906)